LAL

Mediaplanet and RxSight® Team Up to Bring Awareness to Eye Health and Vision Care

Retrieved on: 
Friday, January 6, 2023
Lens, Social media, LAL, Severe cognitive impairment, Patient, Cataract, Ophthalmology, USA Today, Surgery, Telescopic sight, Central Florida

ALISO VIEJO, Calif., Jan. 6, 2023 /PRNewswire-PRWeb/ -- Approximately 32 million Americans reported experiencing vision loss in 2018, and more than half of all Americans will have cataracts by age 80. Luckily, cataract surgery is effective and safe, with 90% of patients reporting improved vision. However, many people report that their post-surgery vision isn't as good as they'd hoped.

Key Points: 
  • Luckily, cataract surgery is effective and safe, with 90% of patients reporting improved vision.
  • However, many people report that their post-surgery vision isn't as good as they'd hoped.
  • The Light Adjustable LensTM (LAL®) by RxSight® is aiming to fix this dilemma by allowing you to test drive your post-cataract surgery vision.
  • The Light Adjustable Lens is a game changer for anyone dealing with cataracts, or anyone concerned for their overall eye health.

Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection

Retrieved on: 
Thursday, December 1, 2022
Health, Medical Devices, General Health, Research, Science, Pharmaceutical, Biotechnology, Nexus, CRL, Government, Automation, LAL, Corporation, Laboratory information management system, Risk, Biotechnology, Surround sound, Nimbus, Patient, Hamilton, Data management, Workflow, Research, Drug development, NYSE, Robotics, QC, NexGen, Water, CSE, LIMS, FDA, Video game console, Management

Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe Nexus 200 , expanding its robust endotoxin testing portfolio.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe Nexus 200 , expanding its robust endotoxin testing portfolio.
  • Automation through robotics represents an evolution of bacterial endotoxin testing and streamlines quality control (QC) processes.
  • Smart automation can improve overall process efficiency, including:
    Minimizing variation, time, and resources of performing laboratory investigations.
  • Since the launch of Endosafe Nexus in 2014, these demands have inspired our Research and Product Development team to reimagine robotic endotoxin testing with the Endosafe Nexus 200.

RxSight, Inc. Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
GLOBE, IOL, Marketing, Investment, Risk, U.S. Securities and Exchange Commission, Technology, Sale, LAL, Visual acuity, SEC, Company, Terminology, Patient, Growth, Security (finance), LDD, Video game, Risk management, Part Two

In the third quarter of 2022, total revenue was $12.6 million, an increase of 118% compared to the third quarter of 2021.

Key Points: 
  • In the third quarter of 2022, total revenue was $12.6 million, an increase of 118% compared to the third quarter of 2021.
  • Total operating expenses for the third quarter of 2022 were $21.3 million, a 47.5% increase from $14.5 million in the third quarter of 2021.
  • Based on its third quarter 2022 performance, RxSight has revised its 2022 full-year revenue guidance to a range of $47.0 million to $48.0 million, compared to prior guidance of $44.0 million to $46.0 million.
  • On Monday, November 7, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, the company will host a conference call to discuss its third quarter 2022 financial results.

Livonia, Avon & Lakeville Railroad Corp. Completes Control Acquisition of Ontario Midland Railroad

Retrieved on: 
Monday, September 19, 2022
Other Transport, Rail, Other Retail, Transport, Specialty, Transportation, Logistics, Supply Chain Management, Supply Chain Management, Retail, Travel, Transport, Workforce, Safety, OMID, B&H Rail Corporation, Surface Transportation Board, Acquisition, WNYP, Growth, Rail transport by country, Ontario Midland Railroad, CSX Transportation, LA, Rail transport, Marketing, Western New York and Pennsylvania Railroad, LAL, Rail freight transport, Mott's

Livonia, Avon & Lakeville Railroad Corporation (LA&L) attained control of the Ontario Midland Railroad Corp. (OMID), which operates more than 50 miles of track in the two counties, with the acquisition of 55% of the companys stock on September 16, 2022.

Key Points: 
  • Livonia, Avon & Lakeville Railroad Corporation (LA&L) attained control of the Ontario Midland Railroad Corp. (OMID), which operates more than 50 miles of track in the two counties, with the acquisition of 55% of the companys stock on September 16, 2022.
  • The acquisition, the terms of which were not disclosed, expands LA&Ls ownership or control to four short line railroads.
  • The Ontario Midland Railroad is headquartered in Sodus, N.Y., interchanges with CSX Transportation at Newark, N.Y. and serves customers handling commodities in the foodservice, chemicals and lumber businesses.
  • The Livonia, Avon & Lakeville Railroad (LAL) operates in Livingston and Monroe Counties, south of Rochester, while B&H Rail Corp. (BH) serves Steuben County, northwest of Corning, NY.

Livonia, Avon & Lakeville Railroads Selects Industry Veteran Robert Babcock to Lead its Sustained Progress

Retrieved on: 
Thursday, September 8, 2022
Supply Chain Management, Retail, Rail, Transport, CEO, Safety, Western New York and Pennsylvania Railroad, Central U.S. hardwood forests, Engineering, BS, American Short Line and Regional Railroad Association, Solution, Institute of Transport Management, B&H Rail Corporation, WNYP, Indiana Rail Road, Babcock, Atchison, Topeka and Santa Fe Railway, Superintendent, General officer, CSX Transportation, Transport, New, LA, General manager, Knowledge, Association, Rail transport, INRD, LAL, Louisville, Kentucky, BNSF Railway, Industry, Marketing, Warehouse, Western New York, Indiana University

To address these opportunities, Livonia, Avon & Lakeville Railroads (LA&L), which operates the Livonia, Avon & Lakeville Railroad (LAL), Western New York & Pennsylvania Railroad (WNYP) and B&H Rail Corp. (BH), has named Robert Babcock as its President and CEO.

Key Points: 
  • To address these opportunities, Livonia, Avon & Lakeville Railroads (LA&L), which operates the Livonia, Avon & Lakeville Railroad (LAL), Western New York & Pennsylvania Railroad (WNYP) and B&H Rail Corp. (BH), has named Robert Babcock as its President and CEO.
  • Babcock, who has experience at both Class I and regional rail lines, assumes his new role September 26, 2022.
  • Robert is a well-respected leader in the rail industry, with in-depth knowledge of practically every facet of the business.
  • Livonia, Avon & Lakeville Railroads safely serves freight customers across western New York and Pennsylvania with pride and distinction, offering multiple interchanges with Class 1 railroads and award-winning logistics solutions.

RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, GLOBE, Form, Technology, Private Securities Litigation Reform Act, SEC, Visual acuity, Terminology, Sale, Prospectus, ATM, Security (finance), Form S-3, EDGAR, Patient, Company, LAL, Attention, BofA Securities, NASDAQ, Share (finance), IOL, 3rd Floor, Time

The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.

Key Points: 
  • The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.
  • As part of the shelf registration, the Company also filed a prospectus supplement to sell, of the $200 million of securities being registered, up to an aggregate of $50 million of its common stock (the "Shares") through an "at-the-market" ("ATM") offering.
  • The registration statement has been filed with the SEC, but has not yet become effective.
  • These securities may not be sold, nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

RxSight, Inc. Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
GLOBE, Technology, Investment, Visual acuity, Sale, Marketing, Patient, LAL, Company, NASDAQ, Â, LDD, IOL, Terminology, Video game, Pharmaceutical industry, Aquaculture

Delivered second quarter 2022 revenue of $11.4 million, an increase of 132% compared to the second quarter of 2021, reflecting:

Key Points: 
  • Delivered second quarter 2022 revenue of $11.4 million, an increase of 132% compared to the second quarter of 2021, reflecting:
    The sale of 49 Light Delivery Devices (LDDs), representing a 96% unit increase from the second quarter of 2021, expanding the installed base to 294 LDDs at the end of the quarter, a 126% increase compared to the 130-unit LDD installed base at the end of the second quarter of 2021.
  • In the second quarter of 2022, total revenue was $11.4 million, an increase of 132% compared to the second quarter of 2021.
  • Total operating expenses for the second quarter of 2022 were $20.6 million, a 57.5% increase from $13.1 million in the second quarter of 2021.
  • On Monday, August 8, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2022 financial results.

RxSight, Inc. to Report Second Quarter 2022 Financial Results on August 8, 2022

Retrieved on: 
Monday, July 25, 2022
IOL, Visual acuity, LAL, GLOBE, NASDAQ, News, Technology, Patient, Investor

ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022.

Key Points: 
  • ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022.
  • The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Instructions are provided (including a dial-in option) to ensure the necessary audio applications are downloaded and installed.
  • RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.

Worldwide Pyrogen Testing Industry to 2027 - Featuring Pacific Biolabs, Sanquin and Thermo Fisher Scientific Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Health, Pharmaceutical, R, Pyrogen, Industry, Therapy, COVID-19, MAT, Safety, Vaccine, Method, RFC, Cancer, Research, Growth, Infection, LAL, Degenerative disease, Coronavirus, Prevalence, Diabetes, RPT, Pharmaceutical industry, Potash

Pyrogen testing is conducted to detect both endotoxin and non-endotoxin pyrogenic contaminants in aqueous parenteral.

Key Points: 
  • Pyrogen testing is conducted to detect both endotoxin and non-endotoxin pyrogenic contaminants in aqueous parenteral.
  • Some of the commonly utilized methods of pyrogen testing include limulus amebocyte lysate (LAL) test, recombinant factor C (rFC) test, rabbit pyrogen test (RPT), and monocyte activation test (MAT).
  • Pyrogen testing finds extensive applications in these industries for the safe development and release of infection-free products at a cost-effective price.
  • What is the structure of the global pyrogen testing market and who are the key players?

RxSight, Inc. Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
Investment, LAL, NASDAQ, GLOBE, Patient, International, Marketing, Sale, Visual acuity, Terminology, LDD, Technology, IOL, Health insurance, Video game

Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million, compared to the prior 2022 guidance range of $40 million to $44 million.

Key Points: 
  • Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million, compared to the prior 2022 guidance range of $40 million to $44 million.
  • In the first quarter of 2022, total revenue was $8.9 million, an increase of 157% compared to the first quarter of 2021.
  • Total operating expenses for the first quarter of 2022 were $20.3 million, a 66% increase from $12.3 million in the first quarter of 2021.
  • On Thursday, May 5, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2022 financial results.